

ASX Announcement

Investor Webinar – Acquisition of License for Azer-cel

Sydney, Australia, 21 August 2023: Imugene Limited (ASX:IMU) (**Company**), a clinical stage immuno-oncology company, is pleased to announce it will hold an investor webinar on Tuesday 22 August 2023 at 11am AEST. The session will be hosted by Managing Director and CEO Leslie Chong, alongside the Company's new COO Dr Bradley Glover.

The webinar will discuss the agreement with Precision Biosciences, Inc. (NASDAQ GS: DTIL) to acquire a worldwide exclusive license to Precision's azer-cel allogeneic CD19 CAR T cell therapy program (see ASX Announcement, 16 August 2023).

Register for the webinar at the following link:

https://us02web.zoom.us/webinar/register/WN_5Pi9U92DTJCCLrmKacl9BQ

Investors are encouraged to send questions prior to the webinar to matt@nwrcommunications.com.au

After registering, you will receive a confirmation email about joining the webinar. A recording will be available at the same link shortly after the conclusion of the session.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au



Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.